205 related articles for article (PubMed ID: 30535358)
1. Biosimilars for Management of Crohn Disease.
Nielsen OH; Ainsworth MA
Ann Intern Med; 2019 Jan; 170(2):129-130. PubMed ID: 30535358
[No Abstract] [Full Text] [Related]
2. Bullying biosimilars: cheaper drugs stymied in USA.
The Lancet Gastroenterology Hepatology
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
[No Abstract] [Full Text] [Related]
3. Biosimilars in paediatric inflammatory bowel disease.
Sieczkowska-Golub J; Jarzebicka D; Oracz G; Kierkus J
World J Gastroenterol; 2018 Sep; 24(35):4021-4027. PubMed ID: 30254406
[TBL] [Abstract][Full Text] [Related]
4. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
5. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.
Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR
Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117
[TBL] [Abstract][Full Text] [Related]
6. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
7. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
[TBL] [Abstract][Full Text] [Related]
8. [Biosimilars: current reality, promising future?].
Agustí Escasany A; Rodríguez Cumplido D
Med Clin (Barc); 2015 Jul; 145(1):18-20. PubMed ID: 25978924
[No Abstract] [Full Text] [Related]
9. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.
Peyrin-Biroulet L; Danese S; Cummings F; Atreya R; Greveson K; Pieper B; Kang T
Expert Rev Gastroenterol Hepatol; 2019 Aug; 13(8):731-738. PubMed ID: 31322440
[No Abstract] [Full Text] [Related]
11. Infliximab or biosimilars in sarcoidosis; to switch or not to switch?
Veltkamp M; Drent M; Baughman RP
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):280-3. PubMed ID: 26847093
[No Abstract] [Full Text] [Related]
12. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
Schellekens H; Lietzan E; Faccin F; Venema J
Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
[TBL] [Abstract][Full Text] [Related]
13. Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance.
Meijboom RW; Barbier L; Druedahl LC; Sarnola K; Tolonen HM; Gardarsdottir H; Egberts TCG; Giezen TJ
Expert Opin Biol Ther; 2023; 23(8):801-817. PubMed ID: 36947408
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in Crohn's disease.
Scheinberg M
J Crohns Colitis; 2014 Jul; 8(7):710. PubMed ID: 24365641
[No Abstract] [Full Text] [Related]
15. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
16. Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
Buer L; Høivik ML; Medhus AW; Moum B
Dig Dis; 2017; 35(1-2):74-82. PubMed ID: 28147370
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars.
Ross A; Richard K
Conn Med; 2015 May; 79(5):295-9. PubMed ID: 26245019
[No Abstract] [Full Text] [Related]
18. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J
Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars versus biologics for inflammatory conditions.
Perry D; Ton J; Kolber MR
Can Fam Physician; 2019 Sep; 65(9):636. PubMed ID: 31515313
[No Abstract] [Full Text] [Related]
20. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
Gils A; Van Stappen T; Dreesen E; Storme R; Vermeire S; Declerck PJ
Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
